Breast Cancer Update
by Dr. Neil Love
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Est. Listeners
Insufficient chart data. Estimates will improve as the show charts.
- Per-Episode Audience
Est. listeners per new episode within ~30 days
N/A🎙 Daily cadence·97 episodes·Last published 1mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
N/A - Active Followers
Loyal subscribers who consistently listen
N/A
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 22 epsHosts
Recent guests
Recent episodes
HER2-Positive Metastatic Breast Cancer — An Interview with Prof Dr Sibylle Loibl on First-Line and Maintenance Therapy
Jul 18, 2026
46m 28s
Localized HR-Positive Breast Cancer — Year in Review Series on Relevant New Datasets and Advances
Jul 13, 2026
58m 12s
For Oncology Nurses: Strategies to Safely and Effectively Implement Antibody-Drug Conjugates — Proceedings from the 2026 Annual ONS Congress
Jul 10, 2026
1h 28m 54s
Antibody-Drug Conjugates in the Management of Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Jul 8, 2026
2h 00m 00s
HR-Positive Breast Cancer — Fifth Annual National General Medical Oncology Summit
Jun 29, 2026
1h 39m 19s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 7/18/26 | HER2-positive metastatic breast cancertreatment outcomes+5 | Prof Dr Sibylle Loibl | trastuzumab deruxtecanpertuzumab+2 | — | HER2-positivemetastatic breast cancer+6 | — | 46m 28s | ||
| 7/13/26 | Localized HR-Positive Breast CancerAdjuvant CDK4/6 Inhibitors+5 | Dr Harold J BursteinDr Joyce O’Shaughnessy | — | — | breast cancerHR-positive+5 | — | 58m 12s | ||
| 7/10/26 | Antibody-Drug ConjugatesBreast Cancer+5 | Ms Courtney ArnMs Jamie Carroll+3 | Antibody-Drug ConjugatesHER2-Targeted ADCs+3 | Breast CancerGynecologic Cancer+2 | Antibody-Drug ConjugatesHER2-Targeted ADCs+7 | — | 1h 28m 54s | ||
| 7/8/26 | Antibody-Drug ConjugatesBreast Cancer Management+5 | Prof Giuseppe CuriglianoProf Rebecca A Dent+2 | ASCO | — | Antibody-Drug ConjugatesBreast Cancer+6 | — | 2h 00m 00s | ||
| 6/29/26 | HR-Positive Breast CancerHER2-Negative Localized Breast Cancer+3 | Dr Erika HamiltonDr Jane Lowe Meisel+2 | National General Medical Oncology Summit | — | breast cancerHR-Positive+5 | — | 1h 39m 19s | ||
| 6/26/26 | Metastatic Triple-Negative Breast CancerFirst-Line Treatment+3 | Dr Kevin PunieDr Tiffany A Traina | BRCA | — | metastatic breast cancertriple-negative+3 | — | 53m 43s | ||
| 6/23/26 | HER2-Positive Breast CancerLocalized Breast Cancer+3 | Dr Erika HamiltonDr Shanu Modi | HER2-Positive Breast Cancer | — | HER2-PositiveBreast Cancer+5 | — | 52m 17s | ||
| 6/22/26 | Desmoid tumorsCryoablation+3 | Prof Bernd Kasper | — | — | desmoid tumorscryoblation+3 | — | 23m 46s | ||
| 6/20/26 | Triple-Negative Breast CancerTROP2-Directed Antibody-Drug Conjugates+3 | Dr Adam M BrufskyDr Kevin Kalinsky | Triple-Negative Breast Cancer | — | breast cancertriple-negative+5 | — | 49m 19s | ||
| 6/11/26 | metastatic breast cancerER-positive+4 | Dr Sara A HurvitzDr Virginia Kaklamani | Fred Hutchinson Cancer CenterUT Health San Antonio MD Anderson Cancer Center | Seattle, WashingtonSan Antonio, Texas | breast cancermetastatic+5 | — | 58m 22s | ||
| 6/2/26 | desmoid tumorstreatment strategies+3 | Prof Bernd Kasper | Mannheim Cancer Center | Mannheim, Germany | desmoid tumorstreatment+3 | — | 22m 50s | ||
| 4/30/26 | breast cancerclinical trials+4 | Dr Aditya BardiaDr Erica Mayer | University of California Los AngelesDana-Farber Cancer Institute | Boston, Massachusetts | oral SERDsbreast cancer+4 | — | 57m 18s | ||
| 4/16/26 | HR-positive metastatic breast cancerbiomarker assessment+3 | Dr Seth Wander | Massachusetts General Hospital | — | HR-positivemetastatic breast cancer+4 | — | 1h 00m 13s | ||
| 4/14/26 | metastatic breast cancerfirst-line therapy+3 | Dr Virginia F BorgesDr Ian E Krop | University of Colorado Anschutz Medical CampusYale Cancer Center | — | ER-positiveHER2-positive+5 | — | 57m 59s | ||
| 4/7/26 | desmoid tumorsclinical data+4 | Dr Ravin Ratan | The University of Texas MD Anderson Cancer Center | — | desmoid tumorsclinical data+5 | — | 28m 14s | ||
| 3/30/26 | hyperglycemiabreast cancer+4 | Ms Jaime CarrollProfessor Giuseppe Curigliano+2 | Mayo ClinicEuropean Institute of Oncology+2 | Rochester, MinnesotaMilan, Italy+2 | hyperglycemiabreast cancer+6 | — | 1h 15m 32s | ||
| 3/18/26 | breast cancercirculating tumor DNA+3 | Dr Lajos Pusztai | Yale Cancer Center | New Haven, Connecticut | breast cancercirculating tumor DNA+3 | — | 30m 21s | ||
| 3/16/26 | desmoid tumorsclinical data+3 | Dr Ravin Ratan | The University of Texas MD Anderson Cancer Center | — | desmoid tumorsclinical data+5 | — | 16m 43s | ||
| 3/2/26 | breast cancerclinical trials+3 | Dr Hope S RugoDr Sara M Tolaney | City of Hope Comprehensive Cancer CenterDana-Farber Cancer Institute | Duarte, CaliforniaBoston, Massachusetts | breast cancerantibody-drug conjugates+3 | — | 58m 40s | ||
| 1/27/26 | HR-positive breast cancerendocrine-based therapy+3 | Dr Angela DeMicheleDr Komal Jhaveri+3 | Abramson Cancer CenterMemorial Sloan Kettering Cancer Center+3 | Philadelphia, PennsylvaniaNew York, New York+2 | breast cancerendocrine therapy+3 | — | 2h 01m 07s | ||
| 1/14/26 | HER2-positive breast cancerclinical data+3 | Prof Giuseppe CuriglianoProf Nadia Harbeck+3 | University of MilanLMU University Hospital+3 | — | HER2-positivebreast cancer+5 | — | 1h 58m 18s | ||
| 1/8/26 | breast cancerantibody-drug conjugates+3 | Dr Javier CortésDr Rita Nanda+2 | International Breast Cancer CenterUniversity of Chicago+2 | Barcelona, SpainLondon, United Kingdom | breast cancerantibody-drug conjugates+3 | — | 1h 30m 21s |
Showing 22 of 22
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.